|1.||Jick, Susan S: 3 articles (05/2010 - 02/2007)|
|2.||Kaye, James A: 2 articles (05/2010 - 01/2010)|
|3.||Hagberg, Katrina W: 2 articles (05/2010 - 01/2010)|
|4.||Loureiro, Manuel: 1 article (08/2010)|
|5.||Gómez-Bernal, Silvia: 1 article (08/2010)|
|6.||Toribio, Jaime: 1 article (08/2010)|
|7.||Rodríguez-Granados, María Teresa: 1 article (08/2010)|
|8.||Hernandez, Rohini K: 1 article (01/2010)|
|9.||Crosignani, PierGiorgio: 1 article (01/2008)|
|10.||Ronsini, Salvatore: 1 article (01/2008)|
05/01/2010 - "ORTHO EVRA and venous thromboembolism: an update."
01/01/2010 - "Concern has been raised that the risk of venous thromboembolism (VTE) in users of the ORTHO EVRA patch is higher compared to users of oral contraceptives (OCs). "
01/01/2010 - "Postmarketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism."
04/01/2005 - "Eleven girls (39%) discontinued Ortho Evra (three lost health insurance, three because of application site reactions, two found patch application schedule difficult to remember, two desired pregnancy, two because of nausea, one because of perceived weight gain). "
01/01/2008 - "As weight gain is one of the most frequently cited reasons for not using and for discontinuing hormonal contraceptives, in an open-label, single-arm, multicentre clinical study we evaluated the effect of the ethinylestradiol/norelgestromin contraceptive patch (EVRA, Janssen-Cilag International, Belgium) on body composition using bioelectrical impedance analysis (BIA). "
04/01/2005 - "About a third (29%) of those with a history of recurrent headaches at initiation reported decrease in headaches, and about a third (33%) of those with acne at initiation reported decrease in facial acne while on Ortho Evra. "
06/01/2005 - "A randomized clinical trial was conducted with 239 women at nine clinical research sites to compare bleeding profile, headache frequency, and subject satisfaction with the transdermal contraceptive, ORTHO EVRA (norelgestromin/ethinyl estradiol transdermal system) used in an extended regimen (84 days) with a traditional, 28-day cyclic regimen. "
02/01/2007 - "Ischemic stroke and acute myocardial infarction are rare among young women who use hormonal contraceptives, and the current data provide no suggestion of an increased risk of either ischemic stroke or acute myocardial infarction in users of the Ortho EVRA contraceptive patch compared with users of norgestimate OCs."
02/01/2007 - "To compare rates of stroke and acute myocardial infarction in users of the Ortho EVRA contraceptive patch with these rates in users of norgestimate-containing oral contraceptives (OCs) with 35 microg of ethinyl estradiol. "
06/01/2007 - "Evra contraceptive patch: risks of thromboembolism."
|1.||Contraceptive Agents (Contraceptives)
|2.||Ethinyl Estradiol (Estinyl)
|5.||Levonorgestrel (Plan B)
|6.||drospirenone and ethinyl estradiol combination (Yasmin)